What does S.A. Laboratoires Pharmaceutiques Trenker do?

S.A. Laboratoires Pharmaceutiques Trenker is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 21 January 1983, 1 establishment.

What is the address of S.A. Laboratoires Pharmaceutiques Trenker?

The registered office of S.A. Laboratoires Pharmaceutiques Trenker is located at Avenue Thomas Edison 32, 1402 Nivelles.

Is S.A. Laboratoires Pharmaceutiques Trenker still active?

Yes. According to the CBE (30 September 2026) S.A. Laboratoires Pharmaceutiques Trenker is active, legal situation “Normale toestand”, started on 21 January 1983.

Is S.A. Laboratoires Pharmaceutiques Trenker registered on Peppol?

Yes, S.A. Laboratoires Pharmaceutiques Trenker is registered on the Peppol network with ID 0208:0423960076.

What is the enterprise number of S.A. Laboratoires Pharmaceutiques Trenker?

The enterprise number of S.A. Laboratoires Pharmaceutiques Trenker is BE0423960076.

When was S.A. Laboratoires Pharmaceutiques Trenker founded?

S.A. Laboratoires Pharmaceutiques Trenker was founded on 21 January 1983.

Who are the directors of S.A. Laboratoires Pharmaceutiques Trenker?

According to the 2025 annual accounts, the directors of S.A. Laboratoires Pharmaceutiques Trenker are: FOXFIN BV SRL, MEDECA BV SRL, ERUDITE BV SRL.

Is S.A. Laboratoires Pharmaceutiques Trenker a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 January 1983; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did S.A. Laboratoires Pharmaceutiques Trenker make in 2025?

S.A. Laboratoires Pharmaceutiques Trenker posted a profit after taxes of € 625,092 in financial year 2025.

What is the revenue of S.A. Laboratoires Pharmaceutiques Trenker?

In its most recent annual accounts (2025), S.A. Laboratoires Pharmaceutiques Trenker reported revenue of € 28,950,903.

How much does an employee at S.A. Laboratoires Pharmaceutiques Trenker earn?

The average wage cost per full-time employee at S.A. Laboratoires Pharmaceutiques Trenker was € 93,000 in 2025: staff costs of € 8.2 million for 88.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does S.A. Laboratoires Pharmaceutiques Trenker have?

According to the 2025 annual accounts, S.A. Laboratoires Pharmaceutiques Trenker has 88.2 full-time equivalents (FTE).

S.A. Laboratoires Pharmaceutiques Trenker (Public Limited)

Dossier S.A. Laboratoires Pharmaceutiques Trenker, printed on 30 September 2026 from databakkes.be/en/0423960076/s-a-laboratoires-pharmaceutiques-trenker. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 62 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

S.A. Laboratoires Pharmaceutiques Trenker from Nivelles, company number BE0423960076, closed financial year 2025 with a result of € 625,092 after tax. For that financial year S.A. Laboratoires Pharmaceutiques Trenker recorded revenue of € 29 million and equity of € 6.4 million. Compared with financial year 2024, the result moved from € 241,517 to € 625,092. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.

What it is worth Growing

€ 6.4 million

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 625,092

▲ 159% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 422,968

▼ 82% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 2.7 million.

People and assets in 2025

Full-time equivalents

88.2

▼ 0.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 10.1 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 8.2 million

▲ 2% vs 2024

€ 93,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 192,201

▼ 46% vs 2024

Of which on lease € 62,464.

Debts at end 2025

Bank debt

€ 6.1 million

▼ 10% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2 million

▼ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 37 days on average.

Taxes and wages

€ 1.6 million

▼ 8% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 27,337,154 Revenue 2022: € 27,337,154 First fiscal year in the series	€ 27,889,587 Revenue 2023: € 27,889,587 ▲ 2% vs 2022 (€ 27,337,154) Favourable step	€ 28,459,252 Revenue 2024: € 28,459,252 ▲ 2% vs 2023 (€ 27,889,587) Favourable step	€ 28,950,903 Revenue 2025: € 28,950,903 ▲ 2% vs 2024 (€ 28,459,252) Favourable step	▲ 2%
Profit after taxes	€ -410,251 Profit after taxes 2022: € -410,251 First fiscal year in the series	€ 816,592 Profit after taxes 2023: € 816,592 ▲ € 1.2 million vs 2022 (€ -410,251) Favourable step	€ 241,517 Profit after taxes 2024: € 241,517 ▼ 70% vs 2023 (€ 816,592) Unfavourable step	€ 625,092 Profit after taxes 2025: € 625,092 ▲ 159% vs 2024 (€ 241,517) Favourable step	▲ 159%
Equity	€ 5,864,691 Equity 2022: € 5,864,691 First fiscal year in the series	€ 5,913,283 Equity 2023: € 5,913,283 ▲ 1% vs 2022 (€ 5,864,691) Favourable step	€ 5,727,800 Equity 2024: € 5,727,800 ▼ 3% vs 2023 (€ 5,913,283) Unfavourable step	€ 6,352,892 Equity 2025: € 6,352,892 ▲ 11% vs 2024 (€ 5,727,800) Favourable step	▲ 11%
Total debts	€ 10,037,845 Total debts 2022: € 10,037,845 First fiscal year in the series	€ 9,592,154 Total debts 2023: € 9,592,154 ▼ 4% vs 2022 (€ 10,037,845) Favourable step	€ 10,901,292 Total debts 2024: € 10,901,292 ▲ 14% vs 2023 (€ 9,592,154) Unfavourable step	€ 9,701,424 Total debts 2025: € 9,701,424 ▼ 11% vs 2024 (€ 10,901,292) Favourable step	▼ 11%
Cash	€ 547,538 Cash 2022: € 547,538 First fiscal year in the series	€ 1,095,192 Cash 2023: € 1,095,192 ▲ 100% vs 2022 (€ 547,538) Favourable step	€ 2,347,099 Cash 2024: € 2,347,099 ▲ 114% vs 2023 (€ 1,095,192) Favourable step	€ 422,968 Cash 2025: € 422,968 ▼ 82% vs 2024 (€ 2,347,099) Unfavourable step	▼ 82%
Retained profit	€ 2,188,259 Retained profit 2022: € 2,188,259 First fiscal year in the series	€ 2,236,851 Retained profit 2023: € 2,236,851 ▲ 2% vs 2022 (€ 2,188,259) Favourable step	€ 2,051,368 Retained profit 2024: € 2,051,368 ▼ 8% vs 2023 (€ 2,236,851) Unfavourable step	€ 2,676,460 Retained profit 2025: € 2,676,460 ▲ 30% vs 2024 (€ 2,051,368) Favourable step	▲ 30%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 768,000 Dividend 2023: € 768,000 Unchanged (€ 0) Unchanged	€ 427,000 Dividend 2024: € 427,000 ▼ 44% vs 2023 (€ 768,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 427,000) Unchanged	▼ 100%
Bank debt	€ 5,518,429 Bank debt 2022: € 5,518,429 First fiscal year in the series	€ 4,733,762 Bank debt 2023: € 4,733,762 ▼ 14% vs 2022 (€ 5,518,429) Favourable step	€ 6,772,407 Bank debt 2024: € 6,772,407 ▲ 43% vs 2023 (€ 4,733,762) Unfavourable step	€ 6,125,001 Bank debt 2025: € 6,125,001 ▼ 10% vs 2024 (€ 6,772,407) Favourable step	▼ 10%
Balance sheet total	€ 15,902,536 Balance sheet total 2022: € 15,902,536 First fiscal year in the series	€ 15,505,437 Balance sheet total 2023: € 15,505,437 ▼ 2% vs 2022 (€ 15,902,536) Unchanged	€ 16,825,975 Balance sheet total 2024: € 16,825,975 ▲ 9% vs 2023 (€ 15,505,437) Unchanged	€ 16,143,497 Balance sheet total 2025: € 16,143,497 ▼ 4% vs 2024 (€ 16,825,975) Unchanged	▼ 4%
Employees (FTE)	95 Employees (FTE) 2022: 95 First fiscal year in the series	90.5 Employees (FTE) 2023: 90.5 ▼ 4.5 vs 2022 (95) Unchanged	88.9 Employees (FTE) 2024: 88.9 ▼ 1.6 vs 2023 (90.5) Unchanged	88.2 Employees (FTE) 2025: 88.2 ▼ 0.7 vs 2024 (88.9) Unchanged	▼ 0.7

Key figures of S.A. Laboratoires Pharmaceutiques Trenker, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to S.A. Laboratoires Pharmaceutiques Trenker?

What happened at S.A. Laboratoires Pharmaceutiques Trenker in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 FOXFIN BV SRL stepped down as director. NBB
2030 MEDECA BV SRL stepped down as director. NBB
2030 ERUDITE BV SRL stepped down as director. NBB
Jun 29, 2026 New annual accounts for financial year 2025: profit of € 625,092 (▲ 159% vs 2024). Source: NBB ↗
2024 FOXFIN BV SRL became a director. NBB
2024 MEDECA BV SRL became a director. NBB
2024 ERUDITE BV SRL became a director. NBB
Jun 14, 2017 New establishment in Nivelles. KBO

In short

From € 410,251 loss in 2022 to € 625,092 profit in 2025.

Paid € 104,851 in corporate taxes since 2022.

Best year ever: 2023, with € 816,592 profit.

Paid out € 1.2 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at S.A. Laboratoires Pharmaceutiques Trenker? We notify you, reason included.

Follow S.A. Laboratoires Pharmaceutiques Trenker

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit